In This Section
Search/Filter
Back to Grantees
Loading...
AACR Grantee indicates novel mechanism to enhance efficacy of immune therapies in high grade serous ovarian cancer

AACR Grantee indicates novel mechanism to enhance efficacy of immune therapies in high grade serous ovarian cancer

Despite demonstrated success in many solid tumor types, immune checkpoint blockade (ICB) agents have minimal efficacy in high grade serous ovarian cancer (HGSC). In this study, the authors describe a novel bispecific anti-PD-1/PD-L1 antibody, which showed increased anti-tumor efficacy compared to mono-specific anti-PD-1 or anti-PDL1. The researchers also...